These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 12111175)

  • 1. The role of antisense oligonucleotides in the treatment of bladder cancer.
    Duggan BJ; Gray S; Johnston SR; Williamson K; Miyaki H; Gleave M
    Urol Res; 2002 Jul; 30(3):137-47. PubMed ID: 12111175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of antisense Bcl-2 oligonucleotides on Bcl-2 protein expression and apoptosis in human bladder transitional cell carcinoma.
    Duggan BJ; Maxwell P; Kelly JD; Canning P; Anderson NH; Keane PF; Johnston SR; Williamson KE
    J Urol; 2001 Sep; 166(3):1098-105. PubMed ID: 11490306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis.
    Frankel SR
    Semin Oncol; 2003 Apr; 30(2):300-4. PubMed ID: 12720157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response of bladder carcinoma cells to TRAIL and antisense oligonucleotide, Bcl-2 or clusterin treatments.
    Sun B; Moibi JA; Mak A; Xiao Z; Roa W; Moore RB
    J Urol; 2009 Mar; 181(3):1361-71. PubMed ID: 19157446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting tumor cell resistance to apoptosis induction with antisense oligonucleotides: progress and therapeutic potential.
    Olie RA; Zangemeister-Wittke U
    Drug Resist Updat; 2001 Feb; 4(1):9-15. PubMed ID: 11512155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells.
    Kraemer K; Fuessel S; Schmidt U; Kotzsch M; Schwenzer B; Wirth MP; Meye A
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3794-800. PubMed ID: 14506173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense oligodeoxynucleotide therapy for bladder cancer: recent advances and future prospects.
    Miyake H; Hara I; Fujisaw M; Gleave ME
    Expert Rev Anticancer Ther; 2005 Dec; 5(6):1001-9. PubMed ID: 16336091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bcl-2 family members as molecular targets in cancer therapy.
    Marzo I; Naval J
    Biochem Pharmacol; 2008 Oct; 76(8):939-46. PubMed ID: 18638457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense oligonucleotide therapy in cancer.
    Stephens AC; Rivers RP
    Curr Opin Mol Ther; 2003 Apr; 5(2):118-22. PubMed ID: 12772500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravesically administered antisense oligonucleotides targeting heat-shock protein-27 inhibit the growth of non-muscle-invasive bladder cancer.
    Hadaschik BA; Jackson J; Fazli L; Zoubeidi A; Burt HM; Gleave ME; So AI
    BJU Int; 2008 Aug; 102(5):610-6. PubMed ID: 18384625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo studies on the availability and toxicity of antisense oligonucleotides in bladder cancer.
    Blietz CE; Thode B; Hauses M; Pries R; Meyer AJ; Doehn C; Jocham D; Kausch I
    In Vivo; 2009; 23(1):13-9. PubMed ID: 19368119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of telomerase with human telomerase reverse transcriptase antisense enhances tumor necrosis factor-alpha-induced apoptosis in bladder cancer cells.
    Gao XD; Chen YR
    Chin Med J (Engl); 2007 May; 120(9):755-60. PubMed ID: 17531113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy.
    Kim R; Emi M; Tanabe K; Toge T
    Cancer; 2004 Dec; 101(11):2491-502. PubMed ID: 15503311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of bcl-2 enhances the efficacy of chemotherapy in renal cell carcinoma.
    Kausch I; Jiang H; Thode B; Doehn C; Krüger S; Jocham D
    Eur Urol; 2005 May; 47(5):703-9. PubMed ID: 15826766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicology of antisense therapeutics.
    Jason TL; Koropatnick J; Berg RW
    Toxicol Appl Pharmacol; 2004 Nov; 201(1):66-83. PubMed ID: 15519609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CpG immunomer DNA enhances antisense protein kinase A RIalpha inhibition of multidrug-resistant colon carcinoma growth in nude mice: molecular basis for combinatorial therapy.
    Nesterova MV; Johnson NR; Stewart T; Abrams S; Cho-Chung YS
    Clin Cancer Res; 2005 Aug; 11(16):5950-5. PubMed ID: 16115938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antisense oligonucleotide therapy in urology.
    Kausch I; Böhle A
    J Urol; 2002 Jul; 168(1):239-47. PubMed ID: 12050550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential roles of antisense therapy in the molecular targeting of genes involved in cancer (review).
    Kim R; Tanabe K; Emi M; Uchida Y; Toge T
    Int J Oncol; 2004 Jan; 24(1):5-17. PubMed ID: 14654935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide.
    Thallinger C; Wolschek MF; Maierhofer H; Skvara H; Pehamberger H; Monia BP; Jansen B; Wacheck V; Selzer E
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4185-91. PubMed ID: 15217956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide): a rational therapeutic to enhance apoptosis in therapy of lung cancer.
    Herbst RS; Frankel SR
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4245s-4248s. PubMed ID: 15217967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.